Corrigendum to "Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study" [Eur Urol 2014;66:489-99].

The diagram listed as Figure 2 inadvertently contained four typographical errors and should be replaced by the figure that is placed below. The number of BRCA1 carriers with prostate-specific antigen ≤3 ng/ml was 731 (not 732), the positive predictive value of biopsy in BRCA1 carriers was 37.5% (not 40.9%); 80.0% (not 60%) of BRCA1 controls and 70.8% (not 68%) of BRCA2 carriers had intermediate/high risk disease. These changes do not change the content (the data are correct in the text and the tables) or the conclusions of the paper.

Fig. 2

Consort diagram for the first round of screening. BRCA1 = breast cancer 1, early onset; BRCA2 = breast cancer 2, early onset; PSA = prostate-specific antigen; PPV = positive predictive value. * Controls were men who had a negative predictive genetic test for the BRCA mutation in their family.